While CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) gene-editing technology has been in the spotlight for years, its full medical potential is yet to be realized. With industry breakthroughs on the horizon, several biotech companies focused on this field are poised for explosive growth. However, it must be noted that CRISPR stocks are generally highly volatile and risky, making them suitable only for aggressive investors with a higher risk tolerance.
Multiple CRISPR companies are currently employing ex vivo (outside the body) or in vivo (inside the body) editing strategies to treat genetic diseases. The technology has also expanded into the cancer treatment arena, particularly in developing CAR-T (Chimeric Antigen Receptor T-cell) therapies, which involve genetically engineering immune cells to precisely attack tumors. Furthermore, CRISPR screening technology, which inactivates genes to identify their specific functions, is playing a crucial role in drug discovery.
Here are three of the most promising CRISPR publicly traded companies to watch in 2025:
With a market capitalization of $5 billion, CRISPR Therapeutics stands out as the only CRISPR-focused company to have progressed beyond the clinical stage. Its partnered therapy with Vertex Pharmaceuticals, Casgevy, received U.S. approval in December 2023 for sickle cell disease and in January 2024 for transfusion-dependent beta-thalassemia.
Its clinical pipeline includes two experimental CAR-T therapies: CTX112 for CD19+ B-cell malignancies and CTX131 for solid tumors and blood cancers. The company is also conducting preclinical research on rare diseases like cystic fibrosis. A strong cash position, bolstered by its partnership and commercialized product, makes this stock relatively less risky within the CRISPR sector.
Beam Therapeutics, valued at $2 billion, utilizes a unique base-editing approach—often compared to a “pencil with an eraser”—that allows for rewriting a single letter of the genome. This technique enables precise targeting of specific gene sequences without the risk of large-scale, unintended genomic rearrangements.
The company currently has three programs in Phase 1/2 clinical trials targeting sickle cell disease, AATD, and the rare genetic disorder GSD1a. Although its development timeline lags behind some peers, the significant long-term potential of its technology supports a premium valuation.
Intellia Therapeutics, with a market cap of $1 billion, has a major collaboration with Regeneron Pharmaceuticals. The partners are evaluating nexiguran ziclumeran (NTLA-2001) in two Phase 3 clinical studies for treating transthyretin amyloidosis (ATTR) with cardiomyopathy and hereditary ATTR amyloidosis with polyneuropathy.
Intellia also fully owns a late-stage program, lonvoguran ziclumeran (NTLA-2002), currently in a Phase 3 study for hereditary angioedema. Additionally, the company is collaborating on a CRISPR-based therapy for hemophilia and researching applications for other genetic diseases, autoimmune conditions, and cancer.
